What is Quality & Compliance (GxP) and when do you need it?
GxP is the umbrella term for the regulated quality systems that govern drug development: GMP for manufacturing, GLP for nonclinical safety studies, GCP for clinical trials, plus GDP for distribution and GVP for pharmacovigilance. Quality and Compliance work is the function that builds those systems, runs them, and proves they hold up when an inspector walks in. It sits inside the CMC and manufacturing stage on this directory because most of the heavy GxP lifting (batch records, deviations, validation, supplier qualification) clusters around making and releasing product, but the discipline reaches across the whole program.
You need it earlier than most first-time sponsors expect. A virtual biotech with no quality team of its own typically brings in a quality consultant before the first GMP batch, to write the quality agreement with the CDMO, set acceptance criteria for release, and stand up a document-control and deviation system that an FDA or EMA reviewer will recognize. From there the demand is continuous: qualifying and auditing your CRO and CDMO vendors, validating the computer systems that hold your data, investigating deviations and out-of-specification results, and getting the site and the paperwork ready for a pre-approval inspection. When something goes wrong, a 483 observation, a warning letter, a data-integrity finding, this is the function that runs the remediation.
The practical reason buyers source this externally is that quality expertise is specialized and lumpy. You do not need a full-time CSV validation lead or a lead auditor every week, but you absolutely need them at specific moments, and getting the wrong person at an inspection is expensive in a way that does not show up until it is too late. Sourcing qualified QA and compliance vendors on demand, for a defined audit, a validation package, or an interim Head of Quality, is how lean teams stay inspection-ready without carrying the headcount.
What does a Quality & Compliance (GxP) CRO or CDMO actually do?
The work splits into a handful of concrete deliverables a buyer can scope and quote. Quality assurance and quality management system build is the foundation: writing or remediating SOPs, document control, change control, deviation and CAPA handling, and the overall quality manual, often delivered as a fit-for-stage QMS for a company that has none. GxP auditing is the most commonly outsourced piece, covering supplier and vendor qualification audits, GMP audits of a CDMO before you commit a campaign, GCP audits of clinical sites and CROs, internal or mock audits, and due-diligence audits ahead of a deal.
Computer system validation (CSV) and the newer computer software assurance (CSA) approach validate the EDC, LIMS, MES, and QMS platforms that hold regulated data, with the validation lifecycle documentation a reviewer expects. Data integrity assessment is its own discipline now, built around the ALCOA+ principles (attributable, legible, contemporaneous, original, accurate, and the rest), checking audit trails, access controls, and whether your records would survive scrutiny. Validation and qualification work extends to equipment and process: IQ, OQ, PQ protocols, cleaning validation, and process validation support.
Two more categories round it out. Regulatory inspection readiness and remediation prepares a site for a pre-approval or routine inspection, runs the mock inspection, and, when needed, writes and executes the response to a Form 483, a warning letter, or an EMA finding. Quality consulting and interim staffing places experienced people into the seat, an interim QP for EU batch release, a contract Head of Quality, or a qualified person for a specific responsibility, while a small company decides whether it needs that role permanently. A single buyer might use one vendor for a CDMO audit, another for a CSV package, and a consultant for inspection prep, which is exactly the kind of multi-vendor program this platform is built to contract once.
How do you choose a Quality & Compliance (GxP) CRO or CDMO?
The selection logic here is different from picking a lab. You are buying judgment and inspection credibility more than bench capacity, so the auditor's or consultant's own track record matters as much as the firm's. The checklist below covers what actually separates a vendor who will hold up under an FDA or EMA inspection from one who produces a tidy report nobody can defend.
- Quality and GxP status: confirm the specific GxP scope you need (GMP, GLP, GCP, GDP, GVP) and that the auditors hold recognized credentials. For EU batch release, verify the firm can supply a qualified QP, not just a generic quality reviewer.
- Regulatory track record by agency: ask how many of their clients have passed FDA, EMA, MHRA, or PMDA inspections, and whether they have led successful 483 or warning-letter remediations. An auditor who has sat through real inspections in your region is worth more than a longer CV.
- Modality and indication fit: a quality system for a sterile injectable, a cell or gene therapy, an ADC, and a small-molecule oral tablet are not interchangeable. Match the vendor to the GxP risks of your modality, since aseptic processing, viral safety, and potent-compound handling each carry their own audit focus.
- Capacity and lead time: auditors and QPs are a scarce, scheduled resource. Confirm named availability against your inspection or batch-release date, because a great auditor booked three months out can miss the window that actually matters.
- Data quality and data integrity depth: ask specifically how they assess ALCOA+ compliance, audit trails, and CSV or CSA documentation. Data-integrity findings are now among the most common serious observations, so a vendor who treats this as a checkbox is a liability.
- IP and confidentiality: quality vendors see your batch records, deviations, and proprietary processes. Confirm strong CDAs, clear handling of audit findings (who they can be shared with), and that competitive conflicts are disclosed before you grant access.